Biotie's nepicastat fails US post-traumatic stress disorder study
This article was originally published in Scrip
Executive Summary
Top-line data from a Phase IIa study evaluating Biotie Therapies' dopamine beta hydroxylase inhibitor nepicastat (SYN117) in combat veterans suffering from post-traumatic stress disorder (PTSD) show that the product was not effective in relieving PTSD-associated symptoms when compared to placebo.